Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 15Neoplasms 10Carcinoma, Renal Cell 8Carcinoma, Hepatocellular 8Melanoma 7Carcinoma, Non-Small-Cell Lung 7Endometrial Neoplasms 6Thyroid Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Recurrence 4Thyroid Cancer, Papillary 3Stomach Neoplasms 3Neuroendocrine Tumors 3Colorectal Neoplasms 3Adenocarcinoma, Follicular 3Ovarian Neoplasms 2Osteosarcoma 2Neoplasm Metastasis 2Lymphoma 2Lung Neoplasms 2Glioma 2Carcinoma, Transitional Cell 2Carcinoma 2Biliary Tract Neoplasms 2Uveal Melanoma 1Triple Negative Breast Neoplasms 1Thyroid cancer, medullary 1Thyroid cancer, Hurthle cell 1Thyroid Diseases 1Thyroid Carcinoma, Anaplastic 1

Interventions

vandetanib 1lenvatinib 1cabozantinib 1Sorafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Thyroid cancer, medullary × lenvatinib × Clear all
NCT03630120 2021-07-14

Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Terminated
6 enrolled 9 charts
EndocrineHead & Neck

Thyroid cancer, medullary, Thyroid Cancer, Papillary, Thyroid Diseases, Thyroid Neoplasms, Adenocarcinoma, Follicular, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡